BIOTESSIA specializes in the import, manufacture, and distribution of diagnostic tests for prevalent diseases in Morocco and Africa, focusing on underserved rural areas. The company aims to enhance maternal and infant health, detect emerging infectious diseases, and provide testing for chronic and cardiovascular conditions, thereby improving healthcare accessibility and outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Access to diagnostic testing for prevalent diseases is limited in underserved rural areas of Morocco and Africa, hindering early detection and timely treatment. This lack of access particularly affects maternal and infant health, the detection of emerging infectious diseases, and the management of chronic conditions.
Solution
BIOTESSIA manufactures and distributes diagnostic tests specifically tailored for prevalent diseases in Morocco and Africa, with a focus on improving healthcare access in rural and secluded areas. By offering affordable and accessible point-of-care (POC) diagnostics, BIOTESSIA aims to strengthen Morocco’s independence in the diagnostics market and contribute to an inclusive healthcare system. The company leverages local manufacturing to lower prices and provides nationwide coverage to ensure tests are available where they are needed most. BIOTESSIA focuses on improving maternal and infant health, detecting emerging infectious diseases, and providing testing for major chronic and cardiovascular diseases.
Target Audience
The primary target audience includes healthcare providers, particularly those serving rural and underserved communities in Morocco and Africa, as well as public health organizations focused on disease prevention and management.
Features
- Local manufacturing to reduce the cost of diagnostic tests
- Point-of-care (POC) testing solutions suitable for remote areas
- Nationwide distribution network ensuring availability across Morocco and Africa
- Expertise in navigating national and international health product regulations
- Partnerships with private and public institutions to promote investment in healthcare resilience